
feb pm et
summari distributor pharmaceut product relat health care servic form via
merger amerisourc corp bergen brunswig corp
price-to-earnings oper ep
perform abil attract new account
compens account loss healthi
oper cash flow howev drug distribut arena
highli competit less diversifi
mani larg health care distribut peer
past perform indic futur perform reli upon
analysi prepar equiti analyst
feb pm stock trade
expect revenu fy sep expand
faster growth experienc
fy benefit increas drug
util includ strong demand see
new drug introduct follow influx
uninsur health system follow
implement afford act
howev see sale growth pressur
slow drug inflat increas price
expect ebitda margin declin slightli
fy fy difficult
gener drug price deflat lower
brand price inflat addit see
price sever new contract contribut
margin pressur fy howev pressur
seen somewhat off-set increas
distribut walgreen
improv purchas drug purchas
joint ventur walgreen
follow share repurchas
benefit tax reform estim
adjust ep fy
oper ep fy exclud
one-tim item period
believ compani outgrow drug
distribut industri due favor
custom product mix compani
sign five year contract extens may
second largest custom express
script esrx expir septemb
howev see ep growth restrict
next unfavor
brand gener drug inflat price
risk opinion target price includ
intensifi competit loss one
major client execut risk relat
integr new walgreen busi
target price appli
forward price-to-earnings multipl low end
fy ep estim valuat
multipl near low end histor
rang warrant given earn growth
pressur see intens price
competit slow brand gener
drug price inflat despit benefit
recent acquisit stronger demand
may ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
execut vice-president chief
corpor overview amerisourcebergen corp one largest pharmaceut distributor
began oper august follow merger amerisourc corp bergen brunswig
corp account merger acquisit amerisourc bergen
distribut oper consist primarili amerisourcebergen drug corp abdc amerisourcebergen
abdc distribut comprehens offer brand name gener pharmaceut over-the-count
health care product home health care suppli equip relat servic wide varieti
health care provid includ acut care hospit health system retail pharmaci mail order
pharmaci medic clinic long-term care custom abdc also provid pharmaci
manag staf consult servic scalabl autom pharmaci dispens
equip medic suppli dispens cabinet suppli manag softwar
absg provid pharmaceut distribut servic primarili physician special
varieti diseas state especi oncolog health care provid includ dialysi clinic
absg also distribut plasma blood product inject pharmaceut vaccin
addit specialti servic busi absg provid drug commerci servic
third-parti logist reimburs consult data analyt outcom research servic
biotech drug compani practic manag group purchas servic physician
march compani enter pharmaceut distribut agreement walgreen
co allianc boot gmbh distribut brand gener drug walgreen
also access gener relat pharmaceut product walgreen boot allianc
develop gmbh global sourc joint ventur walgreen allianc boot believ
ad volum agreement lead improv capac util improv purchas
power may extend contract walgreen
nation retail drugstor chain independ commun drugstor pharmaci depart
supermarket mass merchandis compris compani retail market hospital/acut
care mail order specialti pharmaceut market togeth compris institut market
segment revenu gener sale account fy
total revenu addit sale pharmaci benefit manag express script esrx account
total revenu fy
april acquir world courier group lead global specialti transport logist
provid biopharmaceut industri million cash sale
million world courier strengthen compani servic offer global drug manufactur
provid establish platform expans specialti servic outsid north america
novemb acquir theracom provid reimburs patient support servic
pharmaceut compani million cash pharmerica worker compens busi
revenu million sold octob
competit landscap environ distribut pharmaceut relat health care
solut highli competit nation competitor includ inc
corpor addit compet region local distributor direct-sel manufactur
wareh chain drugstor specialti distributor packag health care technolog
corpor strategi busi strategi focus sole pharmaceut suppli channel
provid value-ad distribut servic solut health care provid compani
believ well posit size market breadth grow distribut busi invest
improv oper capit effici compani also introduc strategi capit
rapid growth project gener drug market also believ one lowest cost
oper structur among pharmaceut distributor pharmaceut distribut
center locat throughout puerto rico acquisit also remain key focu growth
financi trend compani experienc five-year compound annual growth rate revenu
fy fy partial reflect increas margin pressur partial off-set
benefit share repurchas compani experienc five-year compound annual growth rate
normal net incom fy fy
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
neutral sinc februari technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
distributor sub-industri next
month posit outlook base
mainli healthi profit growth see
drug suppli segment gener
compris busi
three larg drug distributor make
bulk market-cap weight
distributor benefit new gener
result patent expir mani
large-sel brand drug view
gener import drug distributor
carri wider margin brand
product howev note drug price inflat
like moder
acquisit strateg partner
sector also increas
cardin
drug-sourc contract
longer term expect larg
distributor realiz high-single-digit
annual ep gain benefit gener drug
penetr age popul drug price
inflat addit expect
million addit american eventu
cover health insur afford
act therefor better abl
afford pharmaceut howev
expect robust growth distributor top line
next year owe patent loss
sever blockbust drug merger among
major drugmak might put pressur
fee distributor receiv
supplier also new health care
legisl expect neg
impact health care coverag long-term
coverag level may neg impact
contributor margin expans
base index
five-year market price perform feb
cost control divestitur
under-perform unit profit
stock benefit acquisit
june health
distributor increas vs
increas composit
sub-industri index
declin versu gain
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
estim revenu growth driven strong
growth specialti distribut extend express script esrx
distribut deal fy sale fy margin widen
expect strong growth wider-margin non-distribut busi /j
amerisourcebergen corpor lift
target price-to-earnings low end rang
fy sep ep estim see valuat pressur
slow ep growth due competit industri price set fy ep
estim dec-q ep vs estim
benefit receiv drug manufactur rebat earlier expect
lower tax share repurchas front-end load see
fundament benefit new commerci busi stabl drug
amerisourcebergen corporaion lower
target price-to-earnings near low end rang
fy sep ep estim see valuat hurt
slow ep growth see intens industri price pressur lower
expect drug price inflat sep-q adjust ep vs
estim benefit recent acquisit partial off-set
custom renew despit near term price pressur expect long term
revenu growth exceed industri growth due abc favor product
custom mix /j agnes
analyst research note compani news
corpor rais target price-to-earnings
near low end abc five-year rang fy sep ep
estim see valuat hurt intens price
competit slow drug price inflat despit benefit
acquisit strength specialti drug see fy ep growth
support tax reform benefit partial off-set
suspens activ outsourc facil lift fy ep
dec-q ep vs estim
tax benefit /joseph agnes
et cfra keep hold opinion share
lower target price-to-earnings near
low end abc rang fy sep ep estim
see valuat hurt intens price competit
slow drug price inflat despit benefit acquisit strength
specialti drug set fy ep sep-q ep vs
estim revenu rose less expect
strength specialti drug non-drug distribut busi partial
off-set lower drug inflat increas gener convers /joseph
et cfra downgrad opinion share
hold buy cut target
price-to-earnings near low end rang fy sep ep
estim cut see valuat restrict unfavor
industri drug price jun-q ep vs estim
lower tax expect revenu growth estim
restrict slow brand gener drug price inflat less
favor custom contract renew despit distribut pressur see ep
support gain consult anim health courier busi /j
announc compani customer-fac offer
align two group pharmaceut distribut strateg
global sourc global commerci servic anim health
financi report purpos oper continu
compris pharmaceut distribut servic report segment
pharmaceut distribut strateg global sourc led
group presid robert mauch includ compani servic retail
chain independ pharmaci health system physician practic
altern care site well sourc repackag
specialti pharmaci capabl peyton howel assum new role
presid health system physician practic strateg health solut
global commerci servic anim health led group
presid jame cleari jr includ compani solut product
commerci patient access well intern develop
anim health also form new manag committe
legal busi offic gina clark chief
commerci servic anim health tim guttman chief
offic robert mauch group presid pharmaceut distribut
execut vice presid presid amerisourcebergen specialti group
decid pursu new opportun outsid compani frari
avail support organ next month transit
role
et cfra keep buy opinion share
corpor keep target price-to-earnings
low end rang fy sep ep estim
think valuat pressur slow ep
growth due competit industri price mar-q adjust ep vs
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
